# DEA Emergency Ban on Experimental Compound SR-17018 Halts Research and Shuts Off Opioid Recovery Alternative

> The US Drug Enforcement Administration has classified the experimental compound SR-17018 as a Schedule I substance, stopping promising university research and cutting off access for people using it to taper off opioids.

**Type:** article · **Category:** Science · **Published:** 2026-11-03 · **Source:** TrendKia
**Canonical:** https://trendkia.com/en/science/dea-emergency-ban-on-experimental-compound-sr-17018-halts-research-and-shuts-off-opioid-recovery-alternative-55707 · **Language:** English
**Tags:** SR-17018, DEA ban, opioid crisis, drug policy, Laura Bohn, Schedule I

When the primary driver of fatal overdoses began transitioning from prescription painkillers to heroin around 2012, researchers were tasked with discovering safer alternatives for pain relief. In 2017, backed by funding from the National Institute on Drug Abuse, a team of scientists reported in the journal Cell that multiple synthetic compounds held promise. Among them was SR-17018, a substance capable of delivering pain relief in mice without triggering respiratory depression, the physiological failure to breathe that typically causes opioid-related deaths.

## From Laboratory Trials to Online Communities
Laura Bohn, senior associate vice president of research at University of South Florida Health, led the team that filed a patent on SR-17018. Subsequent laboratory experiments demonstrated that mice administering the compound did not build a significant tolerance. Furthermore, animals already dependent on morphine, a potent opioid analgesic, were able to use SR-17018 to reset their physiological tolerance without suffering from agonizing withdrawal symptoms.

The application of SR-17018 eventually extended beyond animal models. On digital discussion platforms such as Reddit and Discord, individuals struggling with substance dependency began discussing the chemical as a uniquely effective tool for breaking their addiction to various opioids. Because it had not been designated as a federally controlled substance, the unapproved compound remained relatively accessible online. Concurrently, Laura Bohn was preparing to organize the very first human clinical trials to examine its safety and efficacy under medical supervision.

## The DEA Schedule I Action and Research Obstacles
The trajectory of the research and its online use altered abruptly in late August when the US Drug Enforcement Administration utilized its emergency scheduling authority to place SR-17018 into Schedule I. This restrictive regulatory tier, shared with illicit drugs like heroin, is reserved for substances deemed to have a high abuse liability and no accepted medical value.

The regulatory classification imposes immediate administrative barriers on academic laboratories. Laura Bohn noted that ongoing safety investigations have ground to a halt because researchers are prohibited from manufacturing, handling, or transporting the substance without extensive Schedule I licensing. For people seeking to break their physical dependence outside medical supervision, the ban eliminated an unapproved yet widely sought alternative, despite the absence of formal clinical data in humans.

## Personal Accounts of Tapering and Withdrawal Relief
Jim Bates, a 53-year-old kitchen manager living in Duncan, Oklahoma, had struggled with various substances, including prescription narcotics, heroin, and fentanyl, since age 25. Approximately two years ago, he developed an addiction to 7-OH, a potent alkaloid found in kratom that stimulates opioid receptors in the brain, after buying it at a vape shop. He described the intensity of the substance as being very similar to heroin.

He later switched to MGM-15, another compound that provided an experience comparable to oxycodone. Both 7-OH and MGM-15 were placed into Schedule I by the DEA earlier during the summer. As his dependence deepened, Jim Bates spent months searching Discord and Telegram communities for strategies to detoxify. Roughly 11 months ago, he obtained SR-17018 and used it over three weeks to completely taper off MGM-15.

Unlike previous attempts to discontinue 7-OH, which resulted in intense anxiety and restless legs syndrome, Jim Bates experienced no physical withdrawal symptoms and noted that the compound produced no euphoric high. Another individual, Michael, who withheld his surname for privacy, similarly turned to SR-17018 in January after at least five failed attempts to quit 7-OH. Each previous attempt had involved days of severe illness followed by an extended depressive state. Michael reported that while the chemical did not eliminate every single negative effect, it alleviated his sweating, restlessness, and anxiety sufficiently to allow him to continue working without disrupting his daily routine.

Both men had previously received established medical therapies such as buprenorphine and methadone. However, they expressed a clear preference for SR-17018 because it did not require indefinite daily maintenance, which itself produces protracted withdrawal upon cessation. Michael suggested that regulatory pushback stemmed in part from the compound's potential to disrupt commercial maintenance medication markets that keep patients reliant on long-term treatments.

## Administrative Rationale and Legal Pushback
Prior to the official order, Denver-based attorney Robert Rush submitted a formal petition urging the DEA to reconsider its emergency scheduling. Robert Rush, who serves as the executive director of the nonprofit Rights and Reason Project and represents Laura Bohn in legal matters, argued that SR-17018 presents a markedly lower risk profile than typical illicit synthetic narcotics. The regulatory agency did not issue a direct response to his filing.

In its official notice of intent, the DEA explained its decision to classify SR-17018 alongside three other synthetic opioids. The document highlighted that the National Forensic Laboratory Information System, which monitors substances seized by law enforcement, had identified two samples of SR-17018 across two US states since 2025. Additionally, the Rapid Drug Analysis and Research monitoring framework had detected trace occurrences in the West Coast region.

The DEA maintained that the four synthetic substances lack recognized therapeutic applications and pose trafficking and abuse hazards comparable to standard synthetic opioids based on forensic toxicological exhibits. The agency also noted that because the compound resets physiological opioid tolerance, an individual who returns to active drug use might face an elevated risk of accidental overdose, an outcome that equally occurs following traditional abstinence.

## Implications for Future Dependency Therapies
Robert Rush criticized the emergency regulatory action as disproportionate, emphasizing that the compound has not been linked to emergency medical admissions or documented fatalities. Emergency scheduling remains active for an initial two-year duration with the option for a one-year extension, during which time the agency may seek permanent Schedule I classification through public and scientific proceedings.

A critical feature of the temporary emergency procedure is that it precludes judicial review during the initial enforcement phase. Robert Rush warned that eliminating unregulated retail opioids while simultaneously banning potentially restorative compounds risks exacerbating broader public health challenges. Halting scientific progress on an agent that could underpin next-generation treatments for chemical dependency, he argued, removes a valuable pathway toward solving the chronic addiction crisis.

## What this means for you
The emergency classification of SR-17018 as a Schedule I substance immediately halts academic clinical trials and eliminates an unauthorized pathway used by individuals attempting to quit opioids.

- **Recovery Options:** Individuals self-administering this compound to detoxify from synthetic opioids can no longer purchase it legally. Those struggling with addiction will need to rely on approved medical protocols and standard recovery facilities.
- **Scientific Research:** University laboratories face an immediate suspension of planned human trials and animal safety evaluations. Researchers must navigate lengthy regulatory licensing procedures, which will delay the development of novel pain and dependency therapies.
- **Legal Ramifications:** Being placed in the same category as heroin means possession or distribution of the chemical now carries severe federal criminal penalties. Consumers must avoid purchasing unapproved research chemicals online to prevent severe legal consequences.
- **Reliance on Traditional Treatments:** Patients dependent on maintenance medications like methadone or buprenorphine will continue standard long-term regimens. Rapid off-ramp options that do not involve protracted withdrawal remain unavailable in authorized medicine.

## Why this happened
The Drug Enforcement Administration exercised its temporary emergency powers to restrict SR-17018 after surveillance networks detected the unapproved substance in real-world forensic seizures.

- **Forensic Identifications:** The National Forensic Laboratory Information System detected samples of the chemical in two states beginning in 2025. Regional monitoring networks on the West Coast also confirmed its presence, signaling growing non-laboratory distribution.
- **Risk of Illicit Trafficking:** Regulators determined that because SR-17018 lacks approved medical uses, it carries the potential for unregulated trafficking and abuse similar to other novel synthetic opioids. The agency sought to preempt wider grey-market commercialization before it expanded further.
- **Tolerance Reset Concerns:** Official documentation highlighted that resetting an individual's drug tolerance could leave them physiologically vulnerable to fatal overdoses if they relapse into active opioid use. Legal advocates note, however, that standard abstinence carries the exact same physiological vulnerability.
- **Emergency Regulatory Mechanisms:** Federal statutes permit the agency to place emerging chemicals into Schedule I for a two-year window without immediate judicial review. Regulators utilized this rapid-action mechanism to establish federal control over the substance.

## Questions & Answers

### 1. What is SR-17018 and who discovered its properties?
It is an experimental synthetic compound identified by researcher Laura Bohn and her team at University of South Florida Health as a potentially safer painkiller.

### 2. What did early animal trials reveal about the compound?
Tests in mice showed it relieved pain without inducing lethal respiratory depression and reset tolerance in morphine-dependent animals without causing withdrawal.

### 3. How did the DEA classify SR-17018 in its recent order?
The DEA placed it into Schedule I under emergency powers, categorizing it alongside heroin as a substance with high abuse potential and no accepted medical use.

### 4. Why were people turning to this chemical outside clinical settings?
Individuals found it on online forums and used it to taper off severe opioid dependencies without suffering intense physical withdrawal symptoms.

### 5. How does the federal ban impact ongoing academic research?
Scientists are legally prohibited from synthesizing, shipping, or handling the chemical, effectively halting upcoming human clinical safety trials.

### 6. How long will the emergency scheduling remain in effect?
The emergency classification lasts for two years with a possible one-year extension, during which federal authorities may initiate permanent scheduling.

---
_TrendKia — Har trend, sabse pehle.. Machine-readable view; canonical HTML at the URL above._